Kamikihara Susana Y, Mueller André, Lima Vanessa, Silva Aderbal R T, da Costa Isabela Bazzo, Buratini José, Pupo André S
Department of Pharmacology, Instituto de Biociências, UNESP, Botucatu, São Paulo, Brazil, 18618-000.
J Pharmacol Exp Ther. 2005 Aug;314(2):753-61. doi: 10.1124/jpet.105.087502. Epub 2005 May 4.
The rat tail artery has been used for the study of vasoconstriction mediated by alpha(1A)-adrenoceptors (ARs). However, rings from proximal segments of the tail artery (within the initial 4 cm, PRTA) were at least 3-fold more sensitive to methoxamine and phenylephrine (n = 6-12; p < 0.05) than rings from distal parts (between the sixth and 10th cm, DRTA). Interestingly, the imidazolines N-[5-(4,5-dihydro-1H-imidazol-2-yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide hydrobromide (A-61603) and oxymetazoline, which activate selectively alpha(1A)-ARs, were equipotent in PRTA and DRTA (n = 4-12), whereas buspirone, which activates selectively alpha(1D)-AR, was approximately 70-fold more potent in PRTA than in DRTA (n = 8; p < 0.05). The selective alpha(1D)-AR antagonist 8-[2-[4-(methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride (BMY-7378) was approximately 70-fold more potent against the contractions induced by phenylephrine in PRTA (pK(B) of approximately 8.45; n = 6) than in DRTA (pK(B) of approximately 6.58; n = 6), although the antagonism was complex in PRTA. 5-Methylurapidil, a selective alpha(1A)-antagonist, was equipotent in PRTA and DRTA (pK(B) of approximately 8.4), but the Schild slope in DRTA was 0.73 +/- 0.05 (n = 5). The noncompetitive alpha(1B)-antagonist conotoxin rho-TIA reduced the maximal contraction induced by phenylephrine in DRTA, but not in PRTA. These results indicate a predominant role for alpha(1A)-ARs in the contractions of both PRTA and DRTA but with significant coparticipations of alpha(1D)-ARs in PRTA and alpha(1B)-ARs in DRTA. Semiquantitative reverse transcription-polymerase chain reaction revealed that mRNA encoding alpha(1A)- and alpha(1B)-ARs are similarly distributed in PRTA and DRTA, whereas mRNA for alpha(1D)-ARs is twice more abundant in PRTA. Therefore, alpha(1)-ARs subtypes are differentially distributed along the tail artery. It is important to consider the segment from which the tissue preparation is taken to avoid misinterpretations on receptor mechanisms and drug selectivities.
大鼠尾动脉已被用于研究由α(1A)-肾上腺素能受体(ARs)介导的血管收缩。然而,尾动脉近端节段(起始4厘米内,PRTA)的血管环对甲氧明和去氧肾上腺素的敏感性(n = 6 - 12;p < 0.05)至少比对远端节段(第六至第十厘米之间,DRTA)的血管环高3倍。有趣的是,选择性激活α(1A)-ARs的咪唑啉类化合物N-[5-(4,5-二氢-1H-咪唑-2-基)-2-羟基-5,6,7,8-四氢萘-1-基]甲磺酰胺氢溴酸盐(A-61603)和羟甲唑啉在PRTA和DRTA中效力相当(n = 4 - 12),而选择性激活α(1D)-AR的丁螺环酮在PRTA中的效力比在DRTA中约高70倍(n = 8;p < 0.05)。选择性α(1D)-AR拮抗剂8-[2-[4-(甲氧基苯基)-1-哌嗪基]乙基]-8-氮杂螺[4.5]癸烷-7,9-二酮二盐酸盐(BMY-7378)对PRTA中去氧肾上腺素诱导的收缩的拮抗作用(pK(B)约为8.45;n = 6)比对DRTA中的拮抗作用(pK(B)约为6.58;n = 6)强约70倍,尽管在PRTA中的拮抗作用较为复杂。选择性α(1A)-拮抗剂5-甲基尿嘧啶在PRTA和DRTA中效力相当(pK(B)约为8.4),但在DRTA中的希尔斜率为0.73±0.05(n = 5)。非竞争性α(1B)-拮抗剂芋螺毒素rho-TIA可降低DRTA中去氧肾上腺素诱导的最大收缩,但对PRTA无此作用。这些结果表明,α(1A)-ARs在PRTA和DRTA的收缩中起主要作用,但α(1D)-ARs在PRTA中以及α(1B)-ARs在DRTA中也有显著共同参与。半定量逆转录-聚合酶链反应显示,编码α(1A)-和α(1B)-ARs的mRNA在PRTA和DRTA中的分布相似,而α(1D)-ARs的mRNA在PRTA中的丰度是DRTA中的两倍。因此,α(1)-ARs亚型沿尾动脉呈差异分布。考虑组织制备所取的节段很重要,以避免对受体机制和药物选择性的误解。